Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

Experimental Hematology

Volumn 41, Issue 4, 2013, Pages 387-397.e1

  Bolzoni, Marina ^a   Storti, Paola ^a   Bonomini, Sabrina ^a   Todoerti, Katia ^b   Guasco, Daniela ^a   Toscani, Denise ^a   Agnelli, Luca ^b   Neri, Antonino ^b   Rizzoli, Vittorio ^a   Giuliani, Nicola ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; CELL ADHESION MOLECULE; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 2; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; POMALIDOMIDE; PROTEIN ITGA8; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IN VIVO STUDY; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPROGENITOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; STEM CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84876158316     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.11.005     Document Type: Article

References (40)

1. Palumbo A., Anderson K.C. Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
2. Roodman G.D. Pathogenesis of myeloma bone disease. Leukemia 2009, 23:435-441.
3. Abe M., Hiura K., Wilde J., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104:2484-2491.
4. Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001, 98:11581-11586.
5. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barillé S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001, 98:3527-3533.
6. Giuliani N., Colla S., Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: Focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004, 32:685-691.
7. Giuliani N., Colla S., Sala R., et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002, 100:4615-4621.
8. Colucci S., Brunetti G., Rizzi R., et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004, 104:3722-3730.
9. Abe M., Hiura K., Wilde J., et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002, 100:2195-2202.
10. Choi S.J., Cruz J.C., Craig F., et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000, 96:671-675.
11. Choi S.J., Oba Y., Gazitt Y., et al. Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001, 108:1833-1841.
12. Lee J.W., Chung H.Y., Ehrlich L.A., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103:2308-2315.
13. Quach H., Ritchie D., Stewart A.K., et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010, 24:22-32.
14. Zeldis J.B., Knight R., Hussein M., Chopra R., Muller G. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci 2011, 1222:76-82.
15. Dimopoulos M.A., Palumbo A., Attal M., et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011, 25:749-760.
16. Lacy M.Q., Rajkumar S.V. Pomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. Am J Hematol 2010, 85:95-96.
17. Schey S.A., Fields P., Bartlett J.B., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004, 22:3269-3276.
18. Pan B., Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther 2012, 136:56-68.
19. Breitkreutz I., Raab M.S., Vallet S., et al. Lenalidomide inhibits and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22:1925-1932.
20. Anderson G., Gries M., Kurihara N., et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006, 107:3098-3105.
21. Pal R., Monaghan S.A., Hassett A.C., et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010, 115:605-614.
22. Agnelli L., Forcato M., Ferrari F., et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res 2011, 17:7402-7412.
23. Breitling R., Amtmann A., Herzyk P. Graph-based iterative Group Analysis enhances microarray interpretation. BMC Bioinformatics 2004, 5:100.
24. Keifer J.A., Guttridge D.C., Ashburner B.P., Baldwin A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001, 276:22382-22387.
25. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
26. Escoubet-Lozach L., Lin I.L., Jensen-Pergakes K., et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69:7347-7356.
27. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
28. Reddy N., Hernandez-Ilizaliturri F.J., Deeb G., et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008, 140:36-45.
29. Corral L.G., Haslett P.A., Muller G.W., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163:380-386.
30. Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998, 187:1885-1892.
31. Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
32. Koh K.R., Janz M., Mapara M.Y., et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005, 105:3833-3840.
33. Lacy M.Q. New immunomodulatory drugs in myeloma. Curr Hematol Malig Rep 2011, 6:120-125.
34. Abe M., Hiura K., Ozaki S., Kido S., Matsumoto T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab 2009, 27:16-23.
35. Kurachi T., Morita I., Murota S. Involvement of adhesion molecules LFA-1 and ICAM-1 in osteoclast development. Biochim Biophys Acta 1993, 1178:259-266.
36. Bloemen V., de Vries T.J., Schoenmaker T., Everts V. Intercellular adhesion molecule-1 clusters during osteoclastogenesis. Biochem Biophys Res Commun 2009, 385:640-645.
37. Garcia-Palacios V., Chung H.Y., Choi S.J., et al. Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing ICAM-1 expression. Ann N Y Acad Sci 2006, 1068:240-243.
38. Hayashi H., Nakahama K., Sato T., et al. The role of Mac-1 (CD11b/CD18) in osteoclast differentiation induced by receptor activator of nuclear factor-kappaB ligand. FEBS Lett 2008, 582:3243-3248.
39. Pellat-Deceunynck C., Amiot M., Robillard N., Wijdenes J., Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res 1996, 56:1909-1916.
40. Armoiry X., Aulagner G., Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther 2008, 33:219-226.